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Objective: Venous thromboembolism (VTE) is common in the elderly, but its epidemiology in nursing
home residents remains unclear. This study estimated rates of VTE recorded on nursing home admission
and incidence during residence.
Design: Retrospective analysis of AnalytiCare long term care (LTC) database for the period January 2007 to
June 2009.
Setting: 181 nursing homes in 19 US states.
Participants: Eligible residents had 1 or more admission Minimum Data Set (MDS) 2.0 assessment(s) over
the study period. All VTE cases were extracted if MDS indicated deep vein thrombosis or pulmonary
embolism. The number of admissions and days at risk were estimated from a random sample (n ¼ 1350)
of all residents.
Measurements: The earliest admission was identiﬁed as the admission index date. VTE cases were clas-
siﬁed as either “On Admission” (VTE coded on admission index date) or “During Residence” (coded
afterward). Residents were followed from admission index date until censoring.
Results: A total of 2144 VTE admission cases (3.7% of all admissions) were identiﬁed. A further 757 cases
of VTE occurring during residence were identiﬁed, yielding an incidence of 3.68 cases of VTE per 100
person-years of postadmission residence. VTE admission rates were highest for residents younger than
50 years (4.8%, conﬁdence interval [CI]: 3.9%e5.9%) and 50 to 64 years (5.1%, CI: 4.6%e5.7%) but similar
for those aged 65 to 74 (3.6%, CI: 3.3%e4.0%), 75 to 84 (3.6%, CI: 3.3%e3.9%), and 85 years or older (3.1%,
CI: 2.9%e3.4%). The incidence of VTE during residence was similar among these age strata.
Conclusion: Approximately 1 in 25 nursing home admissions had a VTE diagnosis. VTE incidence during
residence was higher than reported in earlier nursing home studies. These incidence rates merit further
investigation because diagnostic improvements may be driving greater recognition of VTE in LTC.
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undetected until an autopsy is performed.3 Postevent mortality rates
of 7% and 13% have been reported at 1 month4 and 11% and 15% at 6
months for DVT and PE, respectively.5
Acquired risk factors for VTE include previous VTE, frailty, cancer,
hospitalization, surgery, advanced age, venous trauma, immobiliza-
tion, estrogen therapy, inherited/acquired hypercoagulable state,
acute medical illness, pregnancy, antiphospholipid antibodies, and
several other implicated factors.6e11 Silverstein et al6 found that in
the community, the incidence of VTE appears similar in magnitude to
that of stroke: 0.117 per 100 person-years (PY). The incidence of DVT
appears to increase markedly with age.12 Heit et al13 found that in-
stitutionalization (current or recent hospitalization or nursing home
residence) was independently associated with 21.72 odds (among
those with recent surgery) and 7.98 odds (without recent surgery) of
having VTE. In another study, Heit et al14 found that 59% of VTE cases
in the community could be attributed to institutionalization: hospi-
talization for surgery accounted for 24%; hospitalization for medical
illness 22%; and nursing home residence 13%. To facilitate risk
assessment for the unique characteristics of nursing home residents,
a literature-based long term care (LTC) risk stratiﬁcation tool for VTE
has recently been developed by Zarowitz et al.15
In the nursing home setting, 3 studies evaluated the incidence of
VTE diagnosed during facility residence,16e18 and 1 study evaluated
prevalence of asymptomatic disease.19 Using Minnesota Case Mix
Review Program (MCMRP) data for the period 1988 to 1994, Liebson
et al16 found a crude incidence rate of 1.2 (95% conﬁdence interval
[CI]: 0.9e1.5) to 1.5 (95% CI: 1.1e1.9) cases per 100 PY. In the same
study, analysis of a second database (Rochester Epidemiology Project
of Olmstead County, MN, 1998e1994) revealed a crude incidence rate
of 3.6 (95% CI: 3.0e4.2) cases per 100 PY.16 Gomes et al,17 compiling
Minimum Data Set (MDS) and Medicare records for residents in
Kansas for the period 1997 to 1998, found a crude VTE incidence rate
of 1.30 events per 100 PY (95% CI: 1.10e1.51) when excluding warfarin
users. Gatt et al18 evaluated VTE incidence for residents with a length
of stay (LOS) of 3 months or longer in a nursing home in Jerusalem,
Israel, during the period 1991 to 2001. The crude incidence rate of
VTE was similar in both chronically immobilized and mobile cohorts:
1.39 and 1.58 per 100 PY, respectively (P ¼ .77).18
Arpaia et al19 recently concluded that “[d]ata on the frequency of
VTE among nonacute patients nursed at home or in long term care
residential homes are still scarce.” The current study updates earlier
US research regarding the incidence of VTE events that occur during
nursing home residence16,17 and introduces an analysis of the
proportion of nursing home admissions that were coded for VTE.Methods
Data for this study were extracted for the data collection period
January 1, 2007, to June 30, 2009, from the AnalytiCare longitudinal
LTC database (www.analyticare.com). This database included MDS 2.0
assessments, pharmacy dispensing records, and resident character-
istics from 181 nursing home facilities across 19 states (29% of facil-
ities had 0e100 beds, 70% 101e200 beds, 1% >200 beds). All data
provided by AnalytiCare were de-identiﬁed before release for
research in accordance with Health Insurance Portability and
Accountability Act safe-harbor provisions and were exempt from the
requirement for institutional review board review.
AnalytiCare provided data for all residents who had available MDS
and pharmacy data and who had been identiﬁed as having either DVT
(“DVT” checkbox in Section I1 or ICD-9-CM codes of 451.1x, 451.2,
453.2, or 453.4x in Section I3) or PE (415.1x in Section I3) in any MDS
assessment over the study period. To estimate the number of
admissions and days at risk of the total resident population,AnalytiCare separately provided a simple random sample of 1350
residents from the universe of residents (n ¼ 74,019) who had
available MDS and pharmacy data over the study period (reference
sample).
Residents in both groups (census of those with VTE and reference
sample) were considered eligible for analysis if they had 1 or more
admission (or readmission) MDS assessment(s) over the study
period; the earliest MDS admission (or readmission) over the study
period was identiﬁed as the admission index date. Eligible residents
were followed longitudinally from the admission index date until the
end of follow-up (ie, censoring). Follow-up ended on the earliest
occurrence of (1) an MDS assessment coded for VTE (follow-up
equaled zero if VTE was coded on admission); (2) a postindex
discharge that occurred wherein the resident was not readmitted to
the facility within 30 days following discharge; (3) 90 days following
the earliest MDS assessment for which a gap of 120 days or more
occurred between successive MDS assessments; (4) date of death; or
(5) the end of the data collection period.
Cases (eligible residents in the VTE census) were exclusively
deﬁned as either VTE on admission or VTE during residence depending
on whether the date of the earliest VTE-coded MDS assessment
occurred on or after the admission index date, respectively. Counts of
cases were used to supply numerators for the rate of admissions
coded for VTE and the incidence of postadmission VTE cases. The
respective denominatorsdthe total number of initial admissions and
resident days at risk (sum of elapsed days from admission index date
to end of follow-up)dwere estimated from the reference sample.
Data for demographics were derived from the AnalytiCare resi-
dent characteristic data ﬁle. A set of 20 VTE risk factors was obtained
from the risk stratiﬁcation tool developed by Zarowitz et al15 (5 other
risk factors from this tool lacked available data for the current study:
surgical resection of abdominal or pelvic cancer, central vein catheter,
history of VTE, having ﬁrst-degree relative with VTE, and treatment
with erythroid-stimulating agents to hemoglobin greater than 12 g/
dL). Comorbid and VTE risk factor data were obtained from the index
admission MDS assessment and concurrent pharmacy records (45
days of the index date) for those residents with VTE on admission and
was obtained from the index and all postindex MDS assessments and
pharmacy records until censoring for those residents with VTE during
residence and for the reference sample. As a proxy for the Zarowitz
et al15 immobility risk factor checklist (not derivable from the MDS),
immobility was deﬁned as having a score of 24 or higher (where
0 ¼ total independence and 28 ¼ total dependence) using a single
global score from 7 items of activities of daily living in the index MDS
Section G1A, applying the algorithm of Carpenter et al.20Results
From the sampling universe, a total of 58,009 eligible residents
were estimated to have 1 or more admissions (or readmissions) over
the data collection period. The total number of years at risk for
a postadmission VTE (from admission index date until end of follow-
up) across all eligible residents was estimated at 20,586 PY.
A total of 2901 eligible VTE cases were identiﬁed. Of these, 2144
(74%) had VTE identiﬁed on the admission index date. These ac-
counted for 3.7% of the 58,009 estimated admissions (Table 1). The
remaining 757 (26%) of the 2901 VTE cases occurred during residence
in study facilities. For these cases, mean time from admission until
occurrence of the VTE event was 116 days (SD ¼ 162). This yielded
a crude incidence rate of 3.68 VTE cases per 100 PY of postadmission
follow-up (Table 1). Table 1 also shows VTE admission rates and
incidence rates during residence separately by age and gender strata.
Residents younger than 50 and 50 to 64 years of age had dispro-
portionately higher rates of VTE-coded admissions (4.8% and 5.1%)
Table 1
Rate of Admissions Coded for VTE and Incidence Rate of Postadmission VTE Cases
No. Admissions
Coded for VTE
Rate of Admissions Coded




Incidence Rate of Postadmission
VTE Cases per 100 Person-Years
of Postadmission Follow-up (95% CI)
All residents 2144 3.7% (3.5%e3.9%) 757 3.68 (3.42e3.95)
Age, y
<50 98 4.8% (3.9%e5.9%) 21 4.03 (2.50e6.16)
50e64 357 5.1% (4.6%e5.7%) 92 4.51 (3.64e5.53)
65e74 435 3.6% (3.3%e4.0%) 133 3.84 (3.22e4.55)
75e84 720 3.6% (3.3%e3.9%) 259 3.15 (2.78e3.56)
85 534 3.1% (2.9%e3.4%) 252 3.97 (3.50e4.50)
Gender
Male 822 3.6% (3.4%e3.9%) 266 3.65 (3.22e4.11)
Female 1322 3.7% (3.5%e3.9%) 491 3.69 (3.37e4.04)
CI, conﬁdence interval; VTE, venous thromboembolism.
Residents with VTE (n ¼ 2901) were assigned exclusively to either admission or postadmission cases. Only the earliest admission or postadmission VTE event was considered
for this analysis. Rates and conﬁdence intervals for the rate of admissions were derived from exact binomial estimates by dividing admission cases coded for VTE by total
number of estimated admissions. Incidence rates and conﬁdence intervals for postadmission VTE cases were derived from Poisson estimates by dividing number of post-
admission VTE cases observed before censoring by the estimated total number of days from admission to censoring across all residents (exposure).
G. Reardon et al. / JAMDA 14 (2013) 578e584580compared with the remaining age cohorts (3.1%e3.6%). VTE admis-
sion rates and incidence rates for the remaining age and gender
cohorts were similar.
Table 2 shows admission rates (n¼ 1793 cases) and incidence rates
(n ¼ 615 cases) for residents with DVT only and admission rates
(n ¼ 270 cases) and incidence rates (n ¼ 123 cases) for residents with
PE only. The strata of DVTonly and PE only, when combined, accounted
for 97% of all VTE cases; 3% of cases were mixed DVT and PE. DVT only
accounted for 6 admissions for every PE onlyecoded admission and for
5 incident cases for every PE onlyecoded incident case identiﬁed
during residence. Patterns of ﬁndings were similar to those shown in
Table 1 for VTE among age and gender strata, with the exception of
a more homogeneous rate of admissions coded for PE only (shown by
overlapping conﬁdence intervals) across the age strata.
Among the cohort of residents developing VTE on admission,
Table 3 shows the distribution of comorbid conditions and VTE risk
factors by age category. Residents younger than 75 accounted for 42%
of those residents who presented with VTE on admission. Rates of the
comorbid conditions atherosclerotic heart disease, hypertension,
atrial ﬁbrillation, Alzheimer disease, non-Alzheimer dementia, and
osteoarthritis generally increased among older residents (P  .041 for
all distributions by age cohort), as did the VTE risk factors for lower
limb fractures, congestive heart failure, and megestrol therapy
(P  .003 for all age distributions). However, comorbid condition rates
were higher among younger residents for diabetes, depression,
hemiplegia or paralysis, cerebral palsy, multiple sclerosis, seizureTable 2
Rate of Admissions Coded for DVT and PE and Incidence Rate of Postadmission DVT and
Rate of Admissions Coded for DVT
per Total No. of Admissions (95% CI)
Incidence Rate of Postadmission
DVT Cases per 100 Person-Year
Postadmission Follow-Up (95%
All residents 3.1% (3.0%e3.2%) 2.99 (2.76e3.23)
Age, y
<50 4.3% (3.5%e5.3%) 3.46 (2.05e5.46)
50e64 4.3% (3.9%e4.8%) 3.53 (2.76e4.44)
65e74 3.1% (2.8%e3.4%) 3.15 (2.58e3.80)
75e84 2.9% (2.7%e3.2%) 2.66 (2.32e3.04)
85 2.6% (2.4%e2.9%) 3.11 (2.69e3.57)
Gender
Male 3.1% (2.9%e3.4%) 2.87 (2.49e3.28)
Female 3.1% (2.9%e3.2%) 3.05 (2.76e3.37)
CI, conﬁdence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, veno
Residents with VTE were assigned exclusively to either DVT only or PE only and to either
event was considered for this analysis. Combined DVT and PE (not shown in table) accoun
n ¼ 270 admission cases and n ¼ 123 incident cases.disorders, and traumatic brain injury (P  .024 for all age distribu-
tions), as were rates for the VTE risk factors multiple trauma, obesity,
and immobility (P  .033 for all age distributions). The VTE risk
factors stroke, cancer, acute infectious disease, chronic obstructive
pulmonary disease (COPD), congestive heart failure, obesity, and
immobility were highly prevalent in 3 or more of the 5 age groups.
Table 4 shows the distribution of comorbid conditions and VTE
risk factors by age category for the cohort of residents developing VTE
during residence. The count of residents by age category was equiv-
alent for those younger than 75 years, 75 to 84 years, and 85 years or
older. As in the on admission cohort, similar age trends were
observed: the comorbid conditions atherosclerotic heart disease,
hypertension, atrial ﬁbrillation, Alzheimer disease, and non-
Alzheimer dementia generally increased among older residents
(P  .036 for all distributions by age cohort), although only the risk
factor congestive heart failure had a signiﬁcant and consistent
increase with age (P ¼ .010 for age distribution). Similarly, comorbid
condition rates were generally higher among younger residents
having diabetes, hemiplegia or paralysis, cerebral palsy, multiple
sclerosis, seizure disorders, and traumatic brain injury (P  .002 for all
age distributions), whereas only the VTE risk factor obesity decreased
signiﬁcantly with age (P < .001 for age distribution). Similarly, the
VTE risk factors stroke, cancer, acute infectious disease, COPD,
congestive heart failure, obesity, and immobility were highly preva-
lent in 3 or more of the 5 age groups, whereas use of megestrol
therapy was highly prevalent in all age cohorts.PE Cases
s of
CI)
Rate of Admissions Coded for PE per
Total No. of Admissions (95% CI)
Incidence Rate of Postadmission PE
Cases per 100 Person-Years of
Postadmission Follow-Up (95% CI)
0.5% (0.4%e0.5%) 0.60 (0.50e0.71)
0.2% (0.1%e0.6%) 0.58 (0.12e1.68)
0.6% (0.5%e0.8%) 0.88 (0.52e1.39)
0.4% (0.3%e0.6%) 0.64 (0.40e0.96)
0.5% (0.4%e0.6%) 0.40 (0.28e0.56)
0.4% (0.3%e0.5%) 0.74 (0.54e0.99)
0.4% (0.3%e0.5%) 0.71 (0.53e0.93)
0.5% (0.5%e0.6%) 0.53 (0.42e0.68)
us thromboembolism.
admission or postadmission cases. Only the earliest admission or postadmission VTE
ted for 3% of all VTE cases. DVT, n¼ 1793 admission cases and 615 incident cases; PE,
Table 3
Resident Comorbid Conditions and VTE Risk Factors for Admission VTE Cases by Age Strata
<50 Years
(n ¼ 98), %
50e64 Years
(n ¼ 357), %
65e74 Years
(n ¼ 435), %
75e84 Years
(n ¼ 720), %
85 Years
(n ¼ 534), %
P Value
Conditions
Arteriosclerotic heart disease 1 5 11 11 12 <.001
Hypertension 54 66 72 76 74 <.001
Atrial ﬁbrillation 1 3 8 9 11 <.001
Peripheral vascular disease 6 11 12 11 13 .382
Alzheimer disease 0 0 3 6 9 <.001
Dementia other than Alzheimer 2 5 13 23 29 <.001
Transient ischemic attack 1 2 2 3 3 .244
Diabetes mellitus 42 45 46 40 27 <.001
Depression 47 43 36 29 26 <.001
Anemia 31 33 43 38 36 .026
Hemiplegia or paralysis 21 14 8 4 3 <.001
Osteoarthritis 0 4 5 6 6 .041
Cerebral palsy 1 1 0 0 0 .024
Huntington disease 0 0 0 0 0 .415
Multiple sclerosis 4 4 1 1 0 <.001
Parkinson’s disease 0 2 2 4 3 .090
Seizure disorders 26 13 8 8 4 <.001
Traumatic brain injury 4 3 1 1 1 .004
VTE risk factors*
Lower limb orthopedic surgery 0 2 4 2 1 .012
Hip, pelvis, or leg fracture 8 9 6 11 14 .001
Strokey 16 20 21 16 15 .079
Spinal cord injury 1 1 1 0 1 .441
Multiple trauma 5 4 1 1 2 .016
Cancer 10 17 20 19 14 .040
Acute infectious disease 57 49 46 51 51 .330
COPD 13 23 27 23 19 .014
Dehydration 1 1 0 0 0 .252
Congestive heart failure 8 18 24 23 26 .001
Hypercoagulable state 1 0 0 0 0 .106
Inﬂammatory bowel disease 0 1 1 0 1 .551
Obesity (>30% above ideal body weight) 42 52 50 40 29 <.001
Rheumatoid arthritis 0 1 1 1 1 .756
Aromatase inhibitor therapy 0 0 1 1 1 .546
Hormone replacement therapy 0 1 1 1 1 .780
Megestrol acetate therapy 2 4 5 7 9 .003
Selective estrogen receptor modulator therapy 0 0 1 0 1 .231
Immobilityz 18 11 10 9 8 .033
COPD, chronic obstructive pulmonary disease; VTE, venous thromboembolism.
*VTE risk factors obtained from Zarowitz et al.15
yIncludes hemorrhagic and nonhemorrhagic stroke; Zarowitz et al15 list only ischemic (nonhemorrhagic) stroke as a VTE risk factor.
zImmobility deﬁned as having a score of 24 (where 0 ¼ total independence and 28 ¼ total dependence) using a single global score from 7 activity of daily living items in
the index Minimum Data Set Section G1A, applying the algorithm of Carpenter et al.20 Zarowitz et al15 deﬁne immobility as either bedridden, bedridden except for bathroom
privileges, unable to walk at least 10 feet, recent reduction in ability to walk at least 10 feet for at least 72 hours, or lower limb cast.
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studied who did not have VTE on admission or during residence
(n ¼ 1011 after applying exclusion criteria), Table 5 shows, by VTE on
admission and during residence cohorts, the odds ratios (ORs) for
having each of the 20 VTE risk factors with occurrence of VTE. ORs are
separately reported as univariate and adjusted (multivariate logistic
regression of 20 VTE risk factors plus gender). Among the cohort of
residents who developed VTE during residence, residents with the
following risk factors had a signiﬁcantly greater adjusted odds of
having VTE during residence: stroke (OR ¼ 1.51, P < .001), acute
infectious disease (OR ¼ 2.50, P < .001), congestive heart failure
(OR ¼ 1.69, P < .001), obesity (OR ¼ 1.44, P ¼ .001), hormone
replacement therapy (OR ¼ 2.08, P ¼ .048), megestrol therapy
(OR ¼ 2.30, P < .001), and immobility (OR ¼ 1.78, P < .001).Discussion
Kroegel and Reissig1 have described the complexity of assessing
and treating VTE because it “is not a ‘static disease’ but must essen-
tially be understood as a rapid dynamic condition with constantly
changing features with respect to all clinical, radiological, functional,and laboratory ﬁndings.” The current study provides evidence that
a diagnosis of VTE is common among nursing home residents across
all observed age and gender categories. VTE may be encountered as
an existing condition noted on admission, likely originating outside of
the nursing home, and separately, as an acute condition that origi-
nates in the nursing home setting. Regarding the latter group,
a recent report evaluated a subset of residents who developed VTE
during nursing home residence, obtained from the same database
used in the current study.21 Two-thirds of these residents received
warfarin within 45 days of the VTE incident event. Patients who were
underweight, had Alzheimer disease/dementia or cancer, or had
independent physical functioning were less likely to receive warfarin.
Nonpersistence of warfarin therapy was strongly related to antipsy-
chotic use, presence of dementia, and peripheral vascular disease.VTE on Admission
In our study, approximately 1 in 25 initial nursing home admis-
sions had a contemporaneous MDS assessment listing VTE as
a current diagnosis. This is a substantial ﬁnding given the serious
nature of this disease, the potentially short hospital stays before
Table 4
Resident Comorbid Conditions and VTE Risk Factors for Postadmission VTE Cases During Residence by Age Strata
<50 Years
(n ¼ 21), %
50e64 Years
(n ¼ 92), %
65e74 Years
(n ¼ 133), %
75e84 Years
(n ¼ 259), %
85 Years
(n ¼ 252), %
P Value
Conditions
Arteriosclerotic heart disease 5 11 17 23 17 .036
Hypertension 71 67 83 81 79 .034
Atrial ﬁbrillation 5 2 14 15 16 .009
Peripheral vascular disease 19 23 23 31 31 .206
Alzheimer disease 0 2 9 19 25 <.001
Dementia other than Alzheimer 10 16 25 36 40 <.001
Transient ischemic attack 0 1 2 3 4 .427
Diabetes mellitus 43 52 62 50 30 <.001
Depression 52 62 62 61 52 .157
Anemia 38 25 47 41 48 .003
Hemiplegia or paralysis 48 33 17 10 12 <.001
Osteoarthritis 5 8 11 12 13 .482
Cerebral palsy 0 3 0 0 0 <.001
Huntington disease 0 0 0 0 0 d
Multiple sclerosis 10 7 4 2 0 .002
Parkinson disease 0 1 6 10 3 .001
Seizure disorders 43 28 14 11 7 <.001
Traumatic brain injury 19 3 3 2 1 <.001
VTE risk factors
Lower limb orthopedic surgery 5 2 2 2 0 .379
Hip, pelvis, or leg fracture 5 9 11 14 19 .051
Stroke 33 38 32 30 28 .503
Spinal cord injury 0 1 1 0 1 .857
Multiple trauma 10 4 3 4 6 .509
Cancer 5 5 17 9 13 .028
Acute infectious disease 81 65 82 83 81 .006
COPD 0 30 37 29 25 .005
Dehydration 0 0 2 1 2 .674
Congestive heart failure 14 26 39 41 42 .010
Hypercoagulable state 0 0 0 0 1 .196
Inﬂammatory bowel disease 0 0 0 1 0 .426
Obesity (>30% above ideal body weight) 38 61 47 42 30 <.001
Rheumatoid arthritis 0 2 2 3 1 .703
Aromatase inhibitor therapy 0 0 2 0 0 .230
Hormone replacement therapy 0 7 2 4 2 .201
Megestrol acetate therapy 10 9 13 15 16 .476
Selective estrogen receptor modulator therapy 0 0 1 0 1 .709
Immobility 38 12 16 20 18 .062
COPD, chronic obstructive pulmonary disease; VTE, venous thromboembolism.
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hospital discharge. Little is known from published research regarding
how VTE is managed in the nursing home. The VTE event would likely
have originated in the hospital before nursing home transfer. On
admission to the nursing home, a number of concerns are presented
to clinical staff. Because of the lingering potential for sudden death
either directly from existing PE or through the progression of DVT to
PE, these residents would require adequate assessment to review,
modify, and monitor hospital-initiated therapy. Because current
consensus guidelines recommend at least 3 months of anticoagulant
therapy from the start of VTE,2,22 treatment would be expected to
commence in the hospital setting and then continue after nursing
home admission. One concern is whether warfarin is ever initiated
on admission after bridging from short-term low-molecular-weight
heparin or unfractionated heparin. For instance, Caprini et al23
found that only 51% of patients having VTE in the hospital were
discharged with a warfarin prescription, having an average hospital
LOS of only 7.9 days.
VTE During Residence
Even after considering age, evidence suggests that VTE occurs at
a far higher rate among nursing home residents than among
community dwellers. In our study, the incidence rate of 3.68 VTE
cases per 100 PY occurred among residents with a median age of 78years. White et al24 reported communitywide incidence rates of new
VTE cases of only 0.45e0.60 per 100 PY among individuals aged 80
years. White et al24 also found that early mortality after VTE is
strongly associated with presentation of PE, advanced age, cancer,
and underlying cardiovascular disease. As shown in Table 4, a large
proportion of nursing home residents in our study had the latter 3
conditions.
The incidence of diagnosed VTE during residence in the
current study was higher than reported in 3 earlier nursing home
studies16e18 but equivalent to that of a second of 2 databases in one
of these studies.16 Compared with the current study ﬁnding of 3.68
cases per 100 PY, VTE incidence rates in nursing home studies were
1.2 to 1.5 (MCMRP data/Minnesota),16 3.6 (Rochester Epidemiology
Project data/Minnesota),16 1.3 (MDS and Medicare data/Kansas),17
and 1.4 to 1.6 (medical chart data/Israel)18 per 100 PY. The high
incidence rate found in our study may be a consequence of differ-
ences in the pool of nursing homes studied (eg, a potentially greater
number of residents receiving subacute care) or in the methods
used, or it may be due to the later time period (2007e2009) than the
earlier studies (1988e2001). The effect of changes in resident case-
mix or a historic trend in the incidence of VTE remain unknown
given the lack of details in the current and earlier studies regarding
levels of resident acuity and changes in criteria to diagnose VTE.
Findings from the Rochester Epidemiology Project16 would suggest
that the MDS might be undercounting the incidence of fatal
Table 5
Univariate and Adjusted Odds Ratios of Association of VTE Risk Factors With Occurrence of VTE (for Admission VTE Cases and Postadmission VTE Cases During Residence)
Admissions Coded for VTE Postadmission VTE Cases During Residence
Unadjusted Adjusted Unadjusted Adjusted
Odds Ratio P Value Odds Ratio P Value Odds Ratio P Value Odds Ratio P Value
VTE risk factors
Lower limb orthopedic surgery 0.84 .461 0.69 .131 0.47 .042 0.70 .372
Hip, pelvis, or leg fracture 0.83 .118 0.84 .187 1.21 .179 1.27 .143
Stroke 0.76 .003 0.75 .003 1.58 <.001 1.51 <.001
Spinal cord injury 0.62 .146 0.57 .107 0.50 .146 0.57 .280
Multiple trauma 0.72 .167 0.79 .346 1.53 .090 1.53 .146
Age 60 years 0.74 .013 0.75 .023 1.09 .579 0.92 .625
Cancer 1.55 <.001 1.52 <.001 0.96 .807 1.06 .730
Acute infectious disease 0.74 <.001 0.71 <.001 2.93 <.001 2.50 <.001
COPD 0.86 .079 0.88 .174 1.17 .151 0.99 .919
Dehydration 1.26 .735 1.07 .926 3.59 .060 3.51 .075
Congestive heart failure 0.88 .138 0.88 .190 1.89 <.001 1.69 <.001
Hypercoagulable state 1.42 .764 1.36 .794 4.02 .229 3.34 .305
Inﬂammatory bowel disease 1.32 .593 1.11 .846 0.53 .453 0.46 .375
Obesity (>30% above ideal body weight) 1.41 <.001 1.44 <.001 1.40 <.001 1.44 .001
Rheumatoid arthritis 1.48 .337 1.31 .509 2.36 .054 2.11 .113
Aromatase inhibitor therapy 1.15 .762 0.90 .810 0.57 .417 0.64 .550
Hormone replacement therapy 0.61 .187 0.65 .249 2.51 .008 2.08 .048
Megestrol acetate therapy 1.01 .939 1.12 .496 2.46 <.001 2.30 <.001
Selective estrogen receptor modulator therapy 1.01 .982 0.85 .730 0.95 .936 1.31 .667
Immobility 0.97 .828 1.07 .631 1.95 <.001 1.78 <.001
COPD, chronic obstructive pulmonary disease; VTE, venous thromboembolism.
Odds ratios obtained from logistic regression. Adjusted odds ratios were obtained from a multivariate logistic regression of all 20 risk factors plus gender. Referent is the
sample of all residents in the facilities studied not having VTE on admission or during residence (n ¼ 1011 after applying exclusion criteria).
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nursing home discharge are less likely to have VTE recorded in the
ﬁnal MDS assessment. PE events may be especially undercounted. In
a recent national study25 of hospitalizations with a diagnosis of VTE,
the ratio of DVT to PE was much lower than our ﬁndings: crude
estimated average annual rates in that study were 0.152 (DVT) and
0.121 (PE) per 100 hospitalizations, respectively; the relative
proportion due to PE declined with advancing age, although in an
earlier community study,6 the inverse relationship was observed.
The high incidence rate observed in our study might also be
a consequence of the growth in associated risk factors among
hospitalized patients admitted to nursing homes in recent years with
high disease acuity, short hospital stays, and increased use of surgical
and other interventional procedures. Improved diagnostics for
recognizing asymptomatic VTE may be a key factor, although we have
no means of describing how newer diagnostics, such as portable
Doppler ultrasound, have affected incidence rates over time. Stein
et al26 found that the incidence of DVT in hospitalized patients
increased from 0.8% to 1.3% of all hospital admissions over the period
1979 to 1999, yet the incidence of PE remained unchanged at 0.4%.
These authors hypothesized that increased use of venous ultrasound
may have increased DVT incidence, and early diagnosis and treatment
of DVT may have prevented a concurrent rise in PE.26 Our study found
a 1:5 ratio of PE cases to DVT cases during residence. This is lower
than the 1:3 ratio reported in 2 earlier nursing home studies16,18 and
raises the possibility, beyond potential undercounting of PE in the
MDS, of earlier DVT diagnosis and treatment, thus preventing
a concurrent growth in PE rates in the nursing home.
The rate of diagnosed VTE reported in this and earlier nursing
home studies might underestimate the true extent of underlying
disease. The reported prevalence of asymptomatic proximal DVT
(measured through ultrasound screening) was 18% in a study of
patients nursed at home or in nursing homes.19 This rate is so
substantial that if it approximates the true rate of underlying disease,
diagnostic improvements might be expected to drive growth in DVT
incidence for some time to come.Risk Factors for VTE
Whereas residents who have VTE on admission must be managed
therapeutically once theyenter thenursinghome, thosewho are at risk
during residence can receive monitoring and possible interventions to
prevent a VTE episode fromoccurring in theﬁrst place. Thus, a practical
method for risk stratiﬁcation, such as that proposed by Zarowitz et al,15
might be especially beneﬁcial for LTC clinicians. A recent study in this
journal of 376 residents newly admitted or readmitted to 17 LTC facil-
ities has shown that fully 85% of these residents met criteria for VTE
prophylaxis (VTE-P) on admission.27 In the current study, we provide
evidence of strong and independent associationwith incidence of VTE
for 7 of the 20 VTE risk factors that we evaluated: stroke, acute infec-
tious disease, congestive heart failure, obesity, hormone replacement
therapy, megestrol therapy, and immobility.
Although the risk for VTE has been found to increase with age,
a surprising ﬁnding in the current study was the lack of evidence for
age younger than 60 years as an independent predictor for VTE.
Further, a large proportion of younger residents had VTE; admission
and incidence rates during residence for these younger residents were
as high as or higher than those of the older age groups. These ﬁndings
are likely attributable to the unique case-mixof younger nursing home
residents. A closer examination of residents younger than 50 and 50 to
64 years reveals severe levels of disability, apparent with high rates of
neurological disease, cardiovascular disease, diabetes, and cancer, and
high overall VTE risk (multiple trauma, obesity, immobility, stroke,
cancer, acute infectious disease, COPD, congestive heart failure, and
megestrol use), which collectively might be acting to overcome the
potential age-related risk reduction that would otherwise be observed
in younger patients outside of the nursing home setting.
Limitations
Our study had several limitations. First, the study design does not
permit delineation between new VTE events and recurrences of
earlier VTE events that occurred before the start of data collection.
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resident medical chart and may not have adequately captured
emergent VTE, comorbid conditions, and VTE risk factors (eg, lower-
limb orthopedic surgery). Although Poss et al28 indicate that the va-
lidity and reliability of MDS measures can vary differentially by
a given indicator, the MDS 2.0 has been reported to generally have
moderate to moderate-high validity and reliability.29 Wodchis et al30
reported a high sensitivity of 0.80 for 6 of the 10 most-prevalent
discharge diagnoses and moderate sensitivities in the range of 0.60
to 0.79 for another 12, including DVT. Kroegel and Reissig1 have noted
the difﬁculty associated with establishing a VTE diagnosis, thus
illustrating the limitations of comparing studies without adequate
consideration of the study methods used to determine VTE diagnosis.
Finally, data for 5 of 25 VTE risk factors described by Zarowitz et al15
were not available in the current study database. These factors may
also have had an independent association with occurrence of VTE.Conclusions
Further research should seek to test whether, as the possibility
is suggested here, incidence rates of VTE during nursing home resi-
dence are increasing over time and whether such changes are related
to changes in resident acuity or more widespread usage of advanced
diagnostics. Appropriateness of assessment and therapy, dichoto-
mized by cases of VTE on nursing home admission or during
residence, should be evaluated in light of the high mortality risk
linked to VTE.Acknowledgments
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